121 related articles for article (PubMed ID: 28159198)
1. What is the budget impact of a new treatment or new health technology arriving on the market?
Dervaux B; Le Fur C; Dubois S; Josseran A;
Therapie; 2017 Feb; 72(1):93-103. PubMed ID: 28159198
[TBL] [Abstract][Full Text] [Related]
2. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
[TBL] [Abstract][Full Text] [Related]
4. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
[TBL] [Abstract][Full Text] [Related]
5. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
[TBL] [Abstract][Full Text] [Related]
6. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).
Ghabri S; Autin E; Poullié AI; Josselin JM
Pharmacoeconomics; 2018 Apr; 36(4):407-417. PubMed ID: 29247437
[TBL] [Abstract][Full Text] [Related]
7. [HAS budget impact analysis guidelines: A new decision-making tool].
Ghabri S; Poullié AI; Autin E; Josselin JM
Sante Publique; 2017 Oct; 29(4):585-588. PubMed ID: 29034674
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review.
Luo Z; Ruan Z; Yao D; Ung COL; Lai Y; Hu H
Front Public Health; 2021; 9():765999. PubMed ID: 34869180
[No Abstract] [Full Text] [Related]
9. Budget impact analysis.
Leelahavarong P
J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
[TBL] [Abstract][Full Text] [Related]
10. [Guidelines for budget impact analysis of health technologies in Brazil].
Ferreira-Da-Silva AL; Ribeiro RA; Santos VC; Elias FT; d'Oliveira AL; Polanczyk CA
Cad Saude Publica; 2012 Jul; 28(7):1223-38. PubMed ID: 22729254
[TBL] [Abstract][Full Text] [Related]
11. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.
Foroutan N; Tarride JE; Xie F; Jameel B; Mills F; Levine M
J Popul Ther Clin Pharmacol; 2020 Jan; 27(1):e1-e24. PubMed ID: 31922700
[TBL] [Abstract][Full Text] [Related]
12. Defining and Measuring the Affordability of New Medicines: A Systematic Review.
Antoñanzas F; Terkola R; Overton PM; Shalet N; Postma M
Pharmacoeconomics; 2017 Aug; 35(8):777-791. PubMed ID: 28477220
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.
Marshall DA; Douglas PR; Drummond MF; Torrance GW; Macleod S; Manti O; Cheruvu L; Corvari R
Pharmacoeconomics; 2008; 26(6):477-95. PubMed ID: 18489199
[TBL] [Abstract][Full Text] [Related]
14. Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries.
Orlewska E; Mierzejewski P
Value Health; 2004; 7(1):1-10. PubMed ID: 14720125
[TBL] [Abstract][Full Text] [Related]
15. Increasing the impact of budget impact analysis: incorporating uncertainty for decision-makers in small markets.
Hofmeister M; Clement F
Int J Technol Assess Health Care; 2022 Jan; 38(1):e15. PubMed ID: 35080195
[TBL] [Abstract][Full Text] [Related]
16. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of medicines: updated systematic review and implications.
Faleiros DR; Álvares J; Almeida AM; de Araújo VE; Andrade EI; Godman BB; Acurcio FA; Guerra Júnior AA
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):257-66. PubMed ID: 26923561
[TBL] [Abstract][Full Text] [Related]
18. Health economic assessment: a methodological primer.
Simoens S
Int J Environ Res Public Health; 2009 Dec; 6(12):2950-66. PubMed ID: 20049237
[TBL] [Abstract][Full Text] [Related]
19. Role of budget impact in drug reimbursement decisions.
Cohen JP; Stolk E; Niezen M
J Health Polit Policy Law; 2008 Apr; 33(2):225-47. PubMed ID: 18325899
[TBL] [Abstract][Full Text] [Related]
20. Practical issues in handling data input and uncertainty in a budget impact analysis.
Nuijten MJ; Mittendorf T; Persson U
Eur J Health Econ; 2011 Jun; 12(3):231-41. PubMed ID: 20364289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
